Characteristics of the new THOR epithermal neutron beam for BNCT

C. J. Tung; Y. L. Wang; F. Y. Hsu; S. L. Chang; Y. W.H. Liu

doi:10.1016/j.apradiso.2004.05.066

Characteristics of the new THOR epithermal neutron beam for BNCT

C. J. Tung^*, Y. L. Wang, F. Y. Hsu, S. L. Chang, Y. W.H. Liu

^*Corresponding author for this work

Research output: Contribution to journal › Journal Article › peer-review

10 Scopus citations

Abstract

A characterization of the new Tsing Hua open-pool reactor (THOR) epithermal neutron beam designed for boron neutron capture therapy (BNCT) has been performed. The facility is currently under construction and expected in completion in March 2004. The designed epithermal neutron flux for 1MW power is 1.7×10⁹ncm^-2s^-1 in air at the beam exit, accompanied by photon and fast neutron absorbed dose rates of 0.21 and 0.47mGys^-1, respectively. With ¹⁰B concentrations in normal tissue and tumor of 11.4 and 40ppm, the calculated advantage depth dose rate to the modified Snyder head phantom is 0.53RBE-Gymin^-1 at the advantage depth of 85mm, giving an advantage ratio of 4.8. The dose patterns determined by the NCTPlan treatment planning system using the new THOR beam for a patient treated in the Harvard-MIT clinical trial were compared with results of the MITR-II M67 beam. The present study confirms the suitability of the new THOR beam for possible BNCT clinical trials.

Original language	English
Pages (from-to)	861-864
Number of pages	4
Journal	Applied Radiation and Isotopes
Volume	61
Issue number	5
DOIs	https://doi.org/10.1016/j.apradiso.2004.05.066
State	Published - 11 2004
Externally published	Yes

Keywords

BNCT
Boron neutron capture therapy
THOR
Tsing Hua open-pool reactor

Access to Document

10.1016/j.apradiso.2004.05.066

Cite this

@article{9b01780e4e224dd2af9575b4c6917eb9,

title = "Characteristics of the new THOR epithermal neutron beam for BNCT",

abstract = "A characterization of the new Tsing Hua open-pool reactor (THOR) epithermal neutron beam designed for boron neutron capture therapy (BNCT) has been performed. The facility is currently under construction and expected in completion in March 2004. The designed epithermal neutron flux for 1MW power is 1.7×109ncm-2s-1 in air at the beam exit, accompanied by photon and fast neutron absorbed dose rates of 0.21 and 0.47mGys-1, respectively. With 10B concentrations in normal tissue and tumor of 11.4 and 40ppm, the calculated advantage depth dose rate to the modified Snyder head phantom is 0.53RBE-Gymin-1 at the advantage depth of 85mm, giving an advantage ratio of 4.8. The dose patterns determined by the NCTPlan treatment planning system using the new THOR beam for a patient treated in the Harvard-MIT clinical trial were compared with results of the MITR-II M67 beam. The present study confirms the suitability of the new THOR beam for possible BNCT clinical trials.",

keywords = "BNCT, Boron neutron capture therapy, THOR, Tsing Hua open-pool reactor",

author = "Tung, {C. J.} and Wang, {Y. L.} and Hsu, {F. Y.} and Chang, {S. L.} and Liu, {Y. W.H.}",

year = "2004",

month = nov,

doi = "10.1016/j.apradiso.2004.05.066",

language = "英语",

volume = "61",

pages = "861--864",

journal = "Applied Radiation and Isotopes",

issn = "0969-8043",

publisher = "Elsevier Ltd",

number = "5",

}

TY - JOUR

T1 - Characteristics of the new THOR epithermal neutron beam for BNCT

AU - Tung, C. J.

AU - Wang, Y. L.

AU - Hsu, F. Y.

AU - Chang, S. L.

AU - Liu, Y. W.H.

PY - 2004/11

Y1 - 2004/11

N2 - A characterization of the new Tsing Hua open-pool reactor (THOR) epithermal neutron beam designed for boron neutron capture therapy (BNCT) has been performed. The facility is currently under construction and expected in completion in March 2004. The designed epithermal neutron flux for 1MW power is 1.7×109ncm-2s-1 in air at the beam exit, accompanied by photon and fast neutron absorbed dose rates of 0.21 and 0.47mGys-1, respectively. With 10B concentrations in normal tissue and tumor of 11.4 and 40ppm, the calculated advantage depth dose rate to the modified Snyder head phantom is 0.53RBE-Gymin-1 at the advantage depth of 85mm, giving an advantage ratio of 4.8. The dose patterns determined by the NCTPlan treatment planning system using the new THOR beam for a patient treated in the Harvard-MIT clinical trial were compared with results of the MITR-II M67 beam. The present study confirms the suitability of the new THOR beam for possible BNCT clinical trials.

AB - A characterization of the new Tsing Hua open-pool reactor (THOR) epithermal neutron beam designed for boron neutron capture therapy (BNCT) has been performed. The facility is currently under construction and expected in completion in March 2004. The designed epithermal neutron flux for 1MW power is 1.7×109ncm-2s-1 in air at the beam exit, accompanied by photon and fast neutron absorbed dose rates of 0.21 and 0.47mGys-1, respectively. With 10B concentrations in normal tissue and tumor of 11.4 and 40ppm, the calculated advantage depth dose rate to the modified Snyder head phantom is 0.53RBE-Gymin-1 at the advantage depth of 85mm, giving an advantage ratio of 4.8. The dose patterns determined by the NCTPlan treatment planning system using the new THOR beam for a patient treated in the Harvard-MIT clinical trial were compared with results of the MITR-II M67 beam. The present study confirms the suitability of the new THOR beam for possible BNCT clinical trials.

KW - BNCT

KW - Boron neutron capture therapy

KW - THOR

KW - Tsing Hua open-pool reactor

UR - http://www.scopus.com/inward/record.url?scp=4143088291&partnerID=8YFLogxK

U2 - 10.1016/j.apradiso.2004.05.066

DO - 10.1016/j.apradiso.2004.05.066

M3 - 文章

C2 - 15308158

AN - SCOPUS:4143088291

SN - 0969-8043

VL - 61

SP - 861

EP - 864

JO - Applied Radiation and Isotopes

JF - Applied Radiation and Isotopes

IS - 5

ER -

Characteristics of the new THOR epithermal neutron beam for BNCT

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this